Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Phase 3, Randomized, Open-label, Multi-Center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-Muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy SunRISe-5

Disease Sites:

Not Available

Staging:

Phase III

Age Group:

Adults

Therapies:

Not Available

Drugs:

Not Available

Principal Investigator(s):

Luckenbaugh, Amy

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

09-23-2024

Trial Type:

Treatment

Protocol ID:

VICC-DDURO24103

National Clinical Trial ID:

NCT06211764

Related Internal Documents:

View Internal Documents

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available